FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to a human anti-Tie2 antibody, comprising four heavy chain variable regions and four light chain variable regions, two heavy chains and four light chains, as well as a pharmaceutical composition thereof. Also disclosed is use of said human anti-Tie2 antibody for preventing or treating diabetic retinopathy, for preventing or treating critical extremity ischemia, as well as for preventing or treating diabetic macular edema.
EFFECT: invention enables effective treatment of such diseases as critical extremity ischemia, diabetic macular edema and diabetic retinopathy.
14 cl, 7 dwg, 9 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY TO TSLP-RECEPTOR OF HUMAN | 2014 |
|
RU2689528C2 |
| ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
| NOVEL ANTI-HUMAN Igβ ANTIBODY | 2015 |
|
RU2710532C2 |
| BISPECIFIC BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2011 |
|
RU2597973C2 |
| METHOD OF MODIFICATION OF POLYPEPTIDE FOR PURIFICATION OF POLYPEPTIDE MULTIMERS | 2010 |
|
RU2606264C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
| HUMANISED HUMAN OSTEOPONTIN ANTIBODY | 2007 |
|
RU2429016C2 |
